Resolution Therapeutics is systematically evaluating lipid nanoparticle delivery systems paired with mRNA payloads designed to reprogram myeloid cells toward anti-inflammatory phenotypes. This dual-platform approach—combining in vivo LNP optimization with their Phase 1/2 autologous regenerative macrophage therapy—targets a fundamental driver of age-related disease: chronic inflammatory fibrosis.
Key Points
- LNP-mRNA platform targets myeloid compartment reprogramming without inducing inflammatory macrophage
- Parallel assessment protocol accelerates optimal delivery-payload pairing identification by mid-2025
- Platform extension beyond oncology positions regenerative macrophage therapy across multiple fibroti
Longevity Analysis
Macrophage dysfunction—characterized by pathological activation and impaired tissue repair—underpins fibrosis, chronic inflammation, and immune senescence across multiple organ systems. By engineering myeloid cells to adopt reparative rather than pro-inflammatory phenotypes, this approach targets a root cause of age-related disease progression rather than symptomatic management. Success would establish a scalable platform for shifting immune tolerance and tissue regeneration capacity, directly relevant to hepatic, pulmonary, and hematopoietic aging.
Original published by Longevity.Technology.